Overall, this study provides a foundation for defining targets to combat immunosenescence and autoimmune diseases via the GH axis and supports further investigation of GH antagonists like Pegvisomant as potential senolytic therapeutic agents. The gene discussed is GH1; the disease is autoimmune disease.